|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Patient Demographics and Comorbidities | | | | |
| Variable (represented as n (%) unless otherwise stated | | **Removal Cohort**  **(n = 170)** | **Non-Removal Cohort**  **(n = 1263)** | **Total**  **(n = 1433)** | ***p*-value** |
| Age (mean ± standard deviation) | | 63.0 ± 15.7 | 70.0 ± 14.8 | 63.0 ± 14.9 | 1.0 |
| Race | |  |  |  | 0.8 |
| Caucasian | | 153 (90.0) | 1136 (89.9) | 1289 (90.0) |  |
| Black/African American | | 9 (5.3) | 49 (3.9) | 58 (4.1) |  |
| Native American | | 3 (1.8) | 34 (2.7) | 19 (1.3) |  |
| Other or Unknown | | 3 (1.8) | 18 (1.4) | 67 (4.7) |  |
| Hospital Region | |  |  |  | 0.2 |
| Urban | | 164 (96.5) | 1185 (93.8) | 1349 (94.1) |  |
| Rural | | 6 (3.5) | 78 (6.2) | 84 (5.9) |  |
| Prophylactic Antibiotic | |  |  |  | 0.21 |
| 1st Generation Cephalosporins | | 93 (12.4) | 656 (87.6) | 749 (100) |  |
| Aminoglycosides | | 23 (12.0) | 169 (88.0) | 192 (100) |  |
| Clindamycin | | 6 (9.1) | 60 (90.9) | 66 (100) |  |
| Fluoroquinolones | | 27 (14.2) | 163 (85.8) | 190 (100) |  |
| 2nd and 3rd Generation Cephalosporins | | 14 (13.2) | 92 (86.8) | 106 (100) |  |
| Vancomycin | | 7 (5.4) | 123 (94.6) | 130 (100) |  |
| Comorbidities | |  |  |  |  |
| Acid-Base Disorder | | 1 (0.6) | 4 (0.3) | 5 (0.4) | 0.5 |
| Allergies | | 12 (7.0) | 76 (6.0) | 88 (6.1) | 0.6 |
| Genitourinary Atrophy | | 0 (0.0) | 14 (1.1) | 14 (1.0) | 0.4 |
| Urinary Retention | | 5 (2.9) | 36 (2.9) | 41 (2.9) | 0.9 |
| Circulatory | | 15 (8.8) | 130 (10.3) | 145 (10.1) | 0.6 |
| Coagulopathies | | 6 (3.5) | 52 (4.1) | 58 (4.1) | 0.7 |
| Cognitive Impairments | | 1 (0.6) | 5 (0.4) | 6 (0.4) | 0.5 |
| Cystitis | | 0 (0.0) | 19 (1.5) | 19 (1.3) | 0.2 |
| Diabetes | | 37 (21.8) | 241 (19.1) | 278 (19.4) | 0.4 |
| Gut Dysmotility/Inflammation | | 43 (25.3) | 278 (22.0) | 321 (22.4) | 0.3 |
| Dysuria | | 2 (1.2) | 7 (0.6) | 9 (0.6) | 0.3 |
| Electrolyte Disturbances | | 5 (2.9) | 33 (2.6) | 38 (2.7) | 0.8 |
| Hydronephrosis | | 11 (6.5) | 68 (5.4) | 79 (5.5) | 0.6 |
| Hypertension | | 52 (30.6) | 408 (32.3) | 460 (32.1) | 0.7 |
| Hyperlipidemia | | 26 (15.3) | 249 (19.7) | 275 (19.2) | 0.2 |
| Immobility | | 0 (0.0) | 2 (0.2) | 2 (0.1) | 1.0 |
| Immune Disorders | | 1 (0.6) | 21 (1.7) | 22 (1.5) | 0.5 |
| Liver Disease | | 6 (3.5) | 22 (1.7) | 28 (2.0) | 0.1 |
| Degenerative Joint Disease | | 15 (8.8) | 116 (9.2) | 131 (9.1) | 0.9 |
| Neoplasm/Lump | | 4 (2.4) | 49 (3.9) | 53 (3.7) | 0.4 |
| Obesity | | 15 (8.8) | 154 (12.2) | 169 (11.8) | 0.3 |
| Steroid Use | | 0 (0.0) | 4 (0.3) | 4 (0.3) | 1.0 |
| Sexually Transmitted Infections | | 2 (1.2) | 6 (0.5) | 8 (0.6) | 0.2 |
| Current Smoker | | 27 (15.9) | 231 (18.3) | 258 (18.0) | 0.5 |
| History of Thromboembolism | | 13 (7.7) | 101 (8.0) | 114 (8.0) | 0.9 |
| Urinary Frequency | | 35 (20.6) | 335 (26.5) | 370 (25.6) | 0.1 |
| Urinary Incontinence | | 4 (2.6) | 108 (8.6) | 112 (7.8) | 0.003 |
| Renal Disease/Inflammation | | 3 (1.8) | 38 (3.0) | 41 (2.9) | 0.5 |